CellProthera is gearing up for Phase 3 cardiac regeneration trials, moving one step closer to producing clinical batches of ProtheraCytes®, it's stem cell candidate
The Israeli regenerative medicine company is moving one step closer to clinical trials for serious neurological indications such as TBI, spinal cord injury, etc.
TreeFrog has developed a proprietary iPSC manufacturing process called C-Stem, moving one step closer to human trials.
The company will produce its FDA-approved diabetic foot ulcer product and others at the new facility, creating over 200 full-time jobs.
With this designation secured, Cellino is looking to accelerate the commercialization of personalized regenerative therapies.
The company has brought its Japanese manufacturing technology to the USA, and claims this will help provide much biologically younger cell therapies to Americans.
The new Carlsbad facility will provide researchers with critical tools, expertise, and support to rapidly advance cell therapies toward clinical manufacturing.
This collaboration plans to accelerate Japan's regenerative medicine landscape, delivering scalable MSC and EV therapies through state-of-the-art manufacturing technologies.
The new facility at CEPM positions Cell BioEngines to accelerate research and forge partnerships advancing innovative cell therapies.
Leveraging NYBCe's CDMO subsidiary, the companies plan on bridging the gap between Asian and American manufacturing standards. This collaboration seeks to tackle industry-wide GMP capacity challenges, making advanced cell therapies more accessible...
